Evidence mapPaperPMID 40713843Full record

ReviewMolecular neurodegeneration2025

Glycerophospholipids in ALS: insights into disease mechanisms and clinical implication.

Thibaut Burg, Ludo Van Den Bosch

Abstract readReview
In one paragraph

Review in Molecular neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. International journal of nanomedicine · 2026
    Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thibaut BurgDepartement of Neuroscience and Leuven Brain Institute (LBI), KU Leuven - University of Leuven, Campus Gasthuisberg O&N5, Herestraat 49, BP 602, Leuven, 3000, Belgium. thibaut.burg@kuleuven.be.ORCID http://orcid.org/0000-0002-8788-2936
Ludo Van Den BoschDepartement of Neuroscience and Leuven Brain Institute (LBI), KU Leuven - University of Leuven, Campus Gasthuisberg O&N5, Herestraat 49, BP 602, Leuven, 3000, Belgium.

Funding

ABMM ABMMALS Liga België (A cure for ALS) ALS Liga België (A cure for ALS)Fondation Thierry Latran #00099187FWO 12AIK24NFWO G026924NFWO G088523NFWO G0C1620NMuscular Dystrophy Association Muscular Dystrophy AssociationOnderzoeksraad, KU Leuven C14/22/132Onderzoeksraad, KU Leuven IDN/22/ 012Target ALS Target ALS
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease affecting the adult motor system, with no effective treatments available. Despite extensive research efforts, the exact pathological cascade leading to progressive motor neuron degeneration remains elusive. Recent evidence highlights significant modifications in lipid metabolism during ALS progression, even before the onset of motor symptoms. Glycerophospholipids, the primary components of cellular membranes, are frequently altered in ALS patients and models. These lipids not only play a structural role in membranes, but also contribute to cellular metabolism, signaling pathways, and cell type-specific processes such as neuronal transmission and muscle contraction. In this review, we discuss glycerophospholipid physiological functions in the motor system and review recent studies demonstrating their alterations and the possible underlying pathological mechanisms in ALS. Furthermore, we discuss challenges emerging from studying lipid alterations in neurodegeneration and evaluate the therapeutic potential of glycerophospholipids.

Indexed as

Amyotrophic Lateral SclerosisGlycerophospholipidsAnimalsHumansLipid MetabolismMotor NeuronsGlycerophospholipidsAmyotrophic lateral sclerosisGlycerophospholipidLipid metabolismMotor neuronNeurodegeneration

Identifiers

PMID40713843
PMCPMC12297743

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.